bpc 157 human clinical trials evidence 2024 review FDA committee votes 8-6 to make BPC-157 legal. What the FDA briefing report said about the Label Type:No Label TRANSCEND trial: Approved treatments Immune Response

bpc 157 human clinical trials evidence 2024 review FDA committee votes 8-6 to make BPC-157 legal. What the FDA briefing report said about the Label Type:No Label TRANSCEND trial: Approved treatments Immune Response

TRANSCEND trial: Approved treatments are lacking for acquired hypothalamic obesity. New research findings on the efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, are summarized in a Quick Take video: https://nej.md/4eVGFg9

248,249 A randomized controlled trial of 65 patients with new-onset Bell’s palsy tested rTMS targeting the facial nerve region as an add-on to standard therapy, which included corticosteroids, antivirals, oral methylcobalamin, and acupuncture

Immune Response

Label Type:No Label

This distinction matters because BPC-157 is not an FDA-approved component of an approved drug, and FDA has stated that there is insufficient safety information for certain proposed uses and routes